BrainStorm to Present at 2019 Sachs Associates European Life Sciences CEO Forum in Zurich, Switzerland
February 21, 2019 06:00 ET
|
BrainStorm Cell Therapeutics Inc.
ZURICH, Switzerland and NEW YORK, Feb. 21, 2019 (GLOBE NEWSWIRE) -- BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leader in developing innovative autologous cellular therapies for highly...
BrainStorm Issues a Statement to Patients and Shareholders
February 19, 2019 08:06 ET
|
BrainStorm Cell Therapeutics Inc.
NEW YORK, Feb. 19, 2019 (GLOBE NEWSWIRE) -- BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leader in developing innovative autologous cellular therapies for highly debilitating...
BrainStorm to Present at 2019 BIO CEO & Investor Conference and Extracellular Vesicles in Diagnostics & Therapeutics Symposium
February 04, 2019 08:22 ET
|
BrainStorm Cell Therapeutics Inc.
NEW YORK, Feb. 04, 2019 (GLOBE NEWSWIRE) -- BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leader in developing innovative autologous cellular therapies for highly debilitating...
BrainStorm Cell Therapeutics to Present at the 2019 NobleCon15 Annual Investor Conference in Fort Lauderdale, Florida
January 25, 2019 07:15 ET
|
BrainStorm Cell Therapeutics Inc.
NEW YORK, Jan. 25, 2019 (GLOBE NEWSWIRE) -- BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leader in developing innovative autologous cellular therapies for highly debilitating...
BrainStorm Granted Additional Patent for NurOwn® in Israel
January 22, 2019 08:40 ET
|
BrainStorm Cell Therapeutics Inc.
NEW YORK, Jan. 22, 2019 (GLOBE NEWSWIRE) -- BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leader in developing innovative autologous cellular therapies for debilitating neurodegenerative...
BrainStorm to Present NurOwn® Phase 3 Study Update at the 9th Annual California ALS Research Summit in Irvine, CA
January 11, 2019 00:05 ET
|
BrainStorm Cell Therapeutics Inc.
NEW YORK and IRVINE, Calif., Jan. 11, 2019 (GLOBE NEWSWIRE) -- BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leader in developing innovative autologous cellular therapies for highly...
BrainStorm Cell Therapeutics to Present at the 2019 Biotech Showcase and Sachs Associates Neuroscience Innovation Forum at JPM Week
January 03, 2019 06:04 ET
|
BrainStorm Cell Therapeutics Inc.
NEW YORK, Jan. 03, 2019 (GLOBE NEWSWIRE) -- BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell therapeutics for neurodegenerative diseases, announced today that...
BrainStorm Issues 2018 Letter to Shareholders
December 27, 2018 07:35 ET
|
BrainStorm Cell Therapeutics Inc.
NEW YORK, Dec. 27, 2018 (GLOBE NEWSWIRE) -- BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell therapeutics for neurodegenerative diseases, today issued a...
BrainStorm Expands Manufacturing of NurOwn® for Phase 2 Progressive MS Trial
December 26, 2018 01:00 ET
|
BrainStorm Cell Therapeutics Inc.
NEW YORK and BOSTON, Dec. 26, 2018 (GLOBE NEWSWIRE) -- BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell technologies for neurodegenerative diseases, announced...
FDA Accepts BrainStorm’s NurOwn® IND Application for Progressive Multiple Sclerosis
December 17, 2018 07:34 ET
|
BrainStorm Cell Therapeutics Inc.
NEW YORK, Dec. 17, 2018 (GLOBE NEWSWIRE) -- BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of innovative autologous adult stem cell therapeutics for debilitating...